Agoracom Blog

Red Light Holland $TRIP.ca Engages RadixMotion to Develop iMicrodose Digital Care Program Using Latest Immersive Technology $SHRM.ca $RVV.ca $MMED $PLNT.ca

Posted by AGORACOM at 9:09 AM on Tuesday, November 17th, 2020
Red-Light-Holland-Square
  • RadixMotion will design and develop a digital care program for people exploring microdosing
  • The core of the digital care program is a privacy first iMicrodose Journal,
  • A web app where people can anonymously document their microdosing and receive data driven analytics that will help them make informed choices around their usage

Toronto, Ontario–(Newsfile Corp. – November 17, 2020) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (“Red Light Holland” or the “Company“) is pleased to announce that via its Scarlette Lillie Science and Innovation division, it has engaged RadixMotion Inc. (“RadixMotion“), an immersive technology company based in the State of Delaware, to design and develop a digital care program for people exploring microdosing. The program will accompany customers from the first time they encounter iMicrodose products in Smartshops via the iMicrodose Media Information Centre (“iMIC“) with an educational interactive augmented reality app. The core of the digital care program is a privacy first iMicrodose Journal, a web app where people can anonymously document their microdosing and receive data driven analytics that will help them make informed choices around their usage. The app will use Radix Motion’s expertise in biometric human pose data to give people feedback on whether microdosing has measurable effects on reducing their physiological tension or influences other features of their body posture. People using the digital care program will be able to opt in to share their anonymous data with the wider community allowing for substantial advancements in research.

“As access to psychedelics grows we want to provide people with the support they need to make the most out of microdosing via digital health mechanisms, which now includes our iMicrodose digital care program,” said Todd Shapiro, the Chief Executive Officer and Director of the Company. “While other companies in the sector are focused on clinical trials which take years to prove out, this approach of Scarlette Lillie, our science and innovation division, can have immediate benefits. We want to be a part of understanding psilocybin usage now as the mental health crisis is rampant. Gatekeepers can be limiting. We believe in working with informed consumers who are willingly sharing their data.”

‘Digital Health’ is defined as the convergence of digital technologies with health, healthcare, living, and society to enhance the efficiency of healthcare delivery and make it more personalized and precise. Scarlette Lillie is pleased to continue their partnership with Sarah Hashkes, CEO of RadixMotion – who published the first academic paper using the Predictive Coding frameworks to explain what psychedelics do to brains – to create a personalized iMicrodose Journal, a web-based app where people will be able to document their psilocybin use and they will be able to opt in to share their anonymous important data with the community which can then potentially be shared with scientific and medical experts. Microdosing research is at its infancy and this data has huge potential to increase Scarlette Lillie’s understanding rapidly.

“We are excited that our expertise in neuroscience and immersive technology is giving people tools to understand themselves and promoting responsible use of psychedelics. Red Light Holland’s and Scarlette Lillie’s care for their customers is a beacon of hope in the emerging psychedelic market. The consent based approach this program is taking around customers’ data and communicating with customers, we believe, is revolutionary and we hope many companies will follow this example. We are also excited about the AR aspect where customers can receive inspirational messages based on the latest research on wellness when they aim the app at iMicrodose products,” said Sarah Hashkes, CEO of RadixMotion and Scarlette Lillie’s Scientific Advisor. “But where it gets really exciting, as a scientific researcher in psychedelics, is if people do trust us and opt in to share their anonymous data with the community we will have a data set that can take microdosing research to a whole new level. The journal will immediately provide people with analytics about their microdosing so they can find what works best for them, but in the long run, Scarlette Lillie can hopefully use this data, including the unique biometric human pose data, to potentially find out what works best for people all over the world.”

Scarlette Lillie Science and Innovation estimates the total cost for the iMicrodose Digital Care Program, including Augmented Reality for the in-store iMic centres and the iMicrodose web-app Journal to be approximately USD$85,000. The completion of the Augmented Reality for the in-store iMIC remains on pace, expected to be launched before the end of 2020 and the iMicrodose web-app Journal is expected to be completed by RadixMotion and available by the end of Q1 2021.

About Red Light Holland Corp.

The Company is an Ontario-based corporation positioning itself to engage in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: [email protected]
Website: https://redlighttruffles.com/

Tags: , , , , , , ,
Posted in All Recent Posts, Red Light Holland | Comments Off on Red Light Holland $TRIP.ca Engages RadixMotion to Develop iMicrodose Digital Care Program Using Latest Immersive Technology $SHRM.ca $RVV.ca $MMED $PLNT.ca

Lomiko $LMR.ca Forms Technical, Safety, and Sustainability Committee and Charter to Oversee La Loutre Assessment $CJC.ca $SRG.ca $NGC.ca $LLG.ca $GPH.ca $NOU.ca

Posted by AGORACOM at 9:04 AM on Tuesday, November 17th, 2020

Vancouver, B.C., Nov. 17, 2020 (GLOBE NEWSWIRE) — Lomiko Metals Inc. (“Lomiko”) (TSX-V: LMR, OTC: LMRMF, FSE: DH8C) is focused on the exploration and development of flake graphite in Quebec for the new green economy.  Lomiko is pleased to announce the Board of Directors has formed a Technical, Safety, and Sustainability Committee (“LTSSC”), reporting to the Board of Directors.  At the time of formation, the LTSCC is comprised of A. Paul Gill, CEO, and two Independent Directors, Gabriel Erdelyi and Julius Galik.

LTSSC Committee Responsibilities

The LTSSC will oversee the assessment of the La Loutre Flake Graphite Property, and liaise with service providers, technical staff and stakeholders to put forward a series of crucial technical documents including, but not limited to, a Scope of Work (SOW), Graphite Characterization and Metallurgy, Response for Proposal (RFP) on a Preliminary Economic Assessment, and, if required, pre-feasibility, bulk samples, pilot plant, feasibility and construction plans.  The Committee will govern the hiring of technical staff, liaise with extra-company agencies and representatives, and provide a conduit to the Board of Directors to make crucial decisions on the project.

Further additions to the Committee and the Lomiko team are anticipated and will be announced when confirmed.

Lomiko’s Near Term Goals

Graphite demand is expected to increase exponentially for the mined natural graphite material, as more is used in the production of spherical graphite for graphite in the anode portion of Electric Vehicle Lithium-ion batteries.

Lomiko completed a $ 750,000 financing October 23, 2020 and plans to work on its near-term goals:

1) Complete 100% Acquisition of the Property, currently 80% owned by Lomiko Metals.

2) Complete metallurgy and graphite characterization to confirm li-ion anode grade material.

3) Complete a Technical Report to confirm that the extent of the mineralization equals or surpasses the nearby Imerys Mine, owned by an international mining conglomerate.

A “technical report” means a report prepared and filed in accordance with this Instrument and Form 43-101F1 Technical Report, and includes, in summary form, all material scientific and technical information in respect of the subject property as of the effective date of the technical report;

4) Complete Preliminary Economic Assessment (PEA)

A PEA means a study, other than a pre-feasibility or feasibility study, that includes an economic analysis of the potential viability of mineral resources.

For more information on Lomiko Metals, Promethieus, review the website at www.lomiko.com, and www.promethieus.com, contact A. Paul Gill at 604-729-5312 or email: [email protected].

On Behalf of the Board

“A. Paul Gill”

Director, Chief Executive Officer

Tags: , , , , , , , , ,
Posted in All Recent Posts, Lomiko Metals | Comments Off on Lomiko $LMR.ca Forms Technical, Safety, and Sustainability Committee and Charter to Oversee La Loutre Assessment $CJC.ca $SRG.ca $NGC.ca $LLG.ca $GPH.ca $NOU.ca

AGORACOM Small Cap 60: Else Nutrition $BABY.ca $BABYF First Shipment to U.S. Retailers in Time for Christmas and Holiday Shopping, Including a Soon-To-Be Announced, National Major Grocery Chain $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 8:39 AM on Tuesday, November 17th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

KeHE is one of the largest and most well regarded national fresh, natural and organic and specialty food distributors in North America. Else and KeHE have activated five distribution centers in various regions across the U.S. This distribution will enable Else’s first product to be on the shelves of numerous U.S. retail stores, including a soon-to-be announced, national major grocery chain.

Tags: , , , , , , , ,
Posted in AGORACOM Small Cap 60, Else Nutrition Holdings Inc., Featured | Comments Off on AGORACOM Small Cap 60: Else Nutrition $BABY.ca $BABYF First Shipment to U.S. Retailers in Time for Christmas and Holiday Shopping, Including a Soon-To-Be Announced, National Major Grocery Chain $BYND $VERY.ca $INGR $VEGN $TOFB

EVENT: CSE Presents Tech Tuesdays: Israeli Technology Advancements Featuring InnoCan Pharma $INNO.ca $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 7:37 AM on Tuesday, November 17th, 2020
Innocan-Blog

Don’t Miss Tech Tuesdays: Israeli Technology Advancements

The CSE looks forward to co-hosting our next Tech Tuesdays showcase, Israeli Technology Advancements, with the Canada Israel Chamber of Commerce. 

Join us live on November 17th!

Check out the exciting list of featured speakers! 

Don’t miss out on this exclusive glimpse at the cutting-edge technologies hailing from Israel that are making waves internationally. 

Tags: , , , , , , , , ,
Posted in Innocan Pharma Corporation | Comments Off on EVENT: CSE Presents Tech Tuesdays: Israeli Technology Advancements Featuring InnoCan Pharma $INNO.ca $CGC.ca $APHA $OVAT.ca $KHRN.ca

Else Nutrition $BABY.ca $BABYF Commences First Shipment to U.S. Retailers in Time for Christmas and Holiday Shopping $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 7:28 AM on Tuesday, November 17th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Novel, Plant-based Complete Nutrition for Toddlers to hit retail shelves in coming weeks
  • Now commenced shipping its Plant-Based Complete Nutrition for Toddlers to retail stores across the U.S.. 
  • The Company and its distribution partner, KeHE Distributors, has thus far activated five distribution centers in various regions across the U.S.
  • This distribution will enable Else’s first product to very quickly be on the shelves of numerous U.S. retail stores, including a soon-to-be announced, national major grocery chain.

VANCOUVER, BC , Nov. 17, 2020  ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQB: BABYF) (FSE: 0YL) (“Else” or the “Company”) the plant-based baby, toddler and children nutrition company , is pleased to announce that as part of its mission to ensure its novel, plant-based toddler nutrition products will be accessible to health conscious families across North America , that it has now commenced shipping its Plant-Based Complete Nutrition for Toddlers to retail stores across the U.S.. The Company and its distribution partner, KeHE Distributors, has thus far activated five distribution centers in various regions across the U.S. This distribution will enable Else’s first product to very quickly be on the shelves of numerous U.S. retail stores, including a soon-to-be announced, national major grocery chain.

“We are so pleased that Else will be available to consumers on their favourite store shelves in advance of the Christmas holiday,” said Mrs. Hamutal Yitzhak , CEO and Co-Founder of Else. “We are making strong headway now, adding brick and mortar as a core sales vertical, to be complemented by our already-growing e-commerce and Amazon business verticals. We continue to extend our appreciation to KeHE Distributors for its early support of our brand, and anticipate early success and aggressive listings in 2021, as we develop our core retail accounts,” she added.

KeHE Distributors has nearly 70 years of experience servicing store owners and today has a network of over 16 distribution centers across North America . KeHE is one of the largest and most well regarded national fresh, natural and organic and specialty food distributors in North America . Else Nutrition’s agreement with KeHE Distributors secures a retail distribution path of Else’s ground-breaking plant-based toddler nutrition products to thousands of store shelves in the United States , and millions of consumers seeking plant-based alternatives for their children.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents.  Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate.  Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Tags: , , , , , , , , ,
Posted in All Recent Posts, Else Nutrition Holdings Inc., Featured | Comments Off on Else Nutrition $BABY.ca $BABYF Commences First Shipment to U.S. Retailers in Time for Christmas and Holiday Shopping $BYND $VERY.ca $INGR $VEGN $TOFB

AGORACOM Small Cap 60: Avicanna $AVCN.ca $AVCNF Medical #Cannabis Trusted By Physicians and Clinicians $TRUL.ca $ACB

Posted by AGORACOM-JC at 3:06 PM on Monday, November 16th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Aras Azadian Chief Executive Officer and Co-Founder of Avicanna discusses the company’s medical cannabis which is trusted by physicians and clinicians. Azadian states, “Only 5% of physicians are currently prescribing Cannabis.” He continues to explain that the medical community has been skeptical of Canadian Licensed producers. Avicanna provides medical and only medical, this bodes well with the medical community.

Tags: , , , , , , , , , ,
Posted in AGORACOM Small Cap 60, Avicanna Inc. | Comments Off on AGORACOM Small Cap 60: Avicanna $AVCN.ca $AVCNF Medical #Cannabis Trusted By Physicians and Clinicians $TRUL.ca $ACB

A 998-Carat Diamond, the Fifth-Largest Ever, Discovered in Botswana SPONSOR: Arctic Star Exploration $ADD.ca $RIO $DIAM.ca $NAR.ca $MPVD.ca

Posted by AGORACOM at 11:49 AM on Monday, November 16th, 2020
Arctic star logo

SPONSOR: Arctic Star Exploration is currently exploiting the Diagras Diamond Property, NWT. Adjoined by both Diavik and Ekati Mines, Arctic has combined known data on Diagras with modern Gravity and EM geophysical survey techniques to delineate viable Kimberlite targets. Arctic Star is currently preparing a drill program. CLICK HERE FOR MORE INFO

Another week, another huge diamond discovered in Botswana. But “huge” might do this stone a disservice, as it’s actually one of the five largest ever unearthed.

Canadian miner Lucara Diamond Corp has just announced the recovery of a 998-carat high white diamond at its Karowe mine in the southern African nation. The diamond is clivage, meaning it will have to be broken down before it can be processed into polished stones.

Lucara found the massive stone—which measures 2.6 inches x 1.9 inches x 1.8 inches—from direct milling of ore sourced from the south lobe of the mine, according to a press release. It’s just the latest noteworthy diamond discovery at the mine this year. Just in 2020 alone, Karowe has produced 31 diamonds greater than 100 carats, of which 10 are greater than 200 carats and two are greater than 500 carats. The other 500-plus carat stone is a 549-carat diamond named Sethynya that Lucara recently sold to Louis Vuitton.

Even before these recent discoveries, Karowe already had a reputation of producing giant stones. In 2015, the company found a 1,109-carat Lesedi La Rona which sold for $53 million, and shortly after that a 813-carat Constellation stone that went for $63 million, according to Bloomberg. And last year, the Lucara found a 1,758-carat—the second biggest on the planet—which it also sold to Louis Vuitton in February of this year.

“Lucara is extremely pleased with the continued recovery of large high-quality diamonds from the South Lobe of the Karowe mine,” CEO Eira Thomas said in a statement. “To recover two 500-plus carat diamonds in 10 months along with the many other high-quality diamonds across all the size ranges is a testament to the unique aspect of the resource at Karowe and the mine’s ability to recover these large and rare diamonds.”

It remains to be seen what will happen to the diamond now. Lucara did not immediately respond to a request for comment from Robb Report, but did say in the press release that it is evaluating potential steps forward with its cutting and polishing partner, HB Antwerp.

SOURCE: https://www.yahoo.com/lifestyle/998-carat-diamond-fifth-largest-223000002.html

Tags: , , , , , , ,
Posted in All Recent Posts, Arctic Star Diamonds | Comments Off on A 998-Carat Diamond, the Fifth-Largest Ever, Discovered in Botswana SPONSOR: Arctic Star Exploration $ADD.ca $RIO $DIAM.ca $NAR.ca $MPVD.ca

Strapped In, and Fired Up: $TGS.ca and Crimson Wings to host Women’s Car Ball Championship $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 9:15 AM on Monday, November 16th, 2020
TGS Esports Announces Intent to Acquire Canadian Esports and Digital Media Startup, Volcanic Media
  • TGS Esports Inc. (TSXV: TGS) has teamed up with Crimson Wings to host the 3rd season of the Women’s Car Ball Championship, the world’s premier Rocket League tournament explicitly held for women
  • The WCBC is an amazing showcase of women’s esports talent, and we’re helping to make it bigger and more exciting than ever,” said Spiro Khouri , founder and CEO of TGS Esports. “This is going to be an exciting partnership – tons of action, tons of fun, and some of the best casters and hosts around.”

VANCOUVER, BC , Nov. 16, 2020 – Put on your driving gloves, top off the tank, and get ready to experience the utter joy of Rocket League. TGS Esports Inc. ( “TGS” or the ” Company” ) (TSXV: TGS) has teamed up with Crimson Wings to host the 3rd season of the Women’s Car Ball Championship, the world’s premier Rocket League tournament explicitly held for women.

“The WCBC is an amazing showcase of women’s esports talent, and we’re helping to make it bigger and more exciting than ever,” said Spiro Khouri , founder and CEO of TGS Esports. “This is going to be an exciting partnership – tons of action, tons of fun, and some of the best casters and hosts around.”

On November 12 , the WCBC officially announced Season 3 which will kick off December 12 . This season features a partnership with Rocket League developer Psyonix who is already showing support by sharing the news of Season 3 among their network.

The 2020 WCBC features divisions in Europe and North America , pitting teams of three in a round-robin style tournament starting in December. The total prize pool for this season is $10,000 . Jeff “Hunted” Lowe will host the event. Casters include Deep “RJsaurus” Nadar, Andrew “Squidd” Riffe , Layla “TamashiiKanjou” Abbott, and more.

“In its first year of existence, WCBC has given women a solid footing in the world of competitive rocket league, and some tier-one esports organizations use it to scout talent and plan for their future,” said Chase “Kilk” Mitchell , founder and CEO of Crimson Wings Entertainment. “This season, we’re better and stronger than ever, and we’re so excited.”

As part of the kick off for the upcoming 3 rd season TGS and Crimson Wings will be holding two open tournaments for any female Rocket League teams. November 28 th will be open to any teams in Europe while December 5 th will be for North American based teams. Both open events will have a cash prize. More info is available at www.thegamingstadium.com .

“Women are a large and often overlooked segment of the esports community,” Khouri said. “Hosting the WCBC allows us to continue to support these players and to introduce our brand to new competitors.”

For more information, please visit www.thegamingstadium.com or discord.gg/tgs .

Corporate Update
 Further to its news release of November 2, 2020 , the Company has agreed to pay a finder’s fee to Jameel Bharmal in connection with the proposed acquisition of Pepper Esports Inc. by the Company (the ” Acquisition “), subject to the approval of the TSXV.  The finder’s fee is payable by the issuance of 3,870,968 warrants to purchase common shares of TGS at a price of $0.155 for a period of two years following closing of the Acquisition.

About TGS Esports Inc.
 TGS Esports Inc. is an organization focused on creating the ultimate esports experience. TGS is made up of industry professionals with 20+ combined years in the space of tournament organization, league facilitation, and production. This experience combined with the proposed acquisition of Pepper Esports Inc. ( https://www.newswire.ca/news-releases/tgs-esports-announces-signing-of-definitive-agreement-to-acquire-leading-competitive-esports-platform-pepper-esports-804515174.html ) allows TGS to offer a full suite of tools needed for any player or tournament organizer in esports. TGS is also the owner of Canada’s first dedicated esports arena, The Gaming Stadium, located in Richmond, British Columbia , which opened in June 2019.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

On behalf of the Board of Directors
 ” Spiro Khouri “
Spiro Khouri , CEO
TGS Esports Inc.

Disclaimer for Forward-Looking Information
 Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future, including with respect to: the hosting of the Women’s Car Ball Championship tournament; the timing, format and prizes for the tournament; and the proposed acquisition of Pepper Esports Inc. and the finder’s fee payable in connection therewith. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company. The risks include the following: the unknown magnitude and duration of the effects of the COVID-19 pandemic and other risks that are customary to transactions of this nature. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them.

This press release is not an offer of the securities for sale in the United States . The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

View original content to download multimedia: http://www.prnewswire.com/news-releases/strapped-in-and-fired-up-tgs-and-crimson-wings-to-host-womens-car-ball-championship-301173096.html

SOURCE TGS Esports Inc

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Featured, TGS ESports Inc. | Comments Off on Strapped In, and Fired Up: $TGS.ca and Crimson Wings to host Women’s Car Ball Championship $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Innocan $INNO.ca Moves to an Advanced Efficacy Trial on Animals of Its Liposome-CBD Injection, Following Encouraging Results on the First Stage $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 7:58 AM on Monday, November 16th, 2020
Innocan-Blog
  • Announced today the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan’s CBD loaded liposome platform technology (“LPT”) in relevant diseases
  • These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and rats after a single injection
  • The new studies will be conducted by the Hebrew University of Jerusalem

Herzliya, Israel and Calgary, Alberta–(November 16, 2020) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan’s CBD loaded liposome platform technology (“LPT”) in relevant diseases. These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and rats after a single injection. The new studies will be conducted by the Hebrew University of Jerusalem.

The original study which was led by Dr. Ahuva Cern, Senior Researcher in the lab of Prof. Barenholz at the Hebrew University in Jerusalem found significant amounts of CBD in mices’ blood and muscles up to 21 days after they were injected intramuscular with a single injection of CBD using LPT. The same findings were also demonstrated in rats.

These results are substantial when compared to oral or smoking administration of CBD, in which CBD was found in the blood only for a period of up to 36 hours after one administration.

The results of this study may indicate that Innocan’s LPT, with an injection only once or twice a month, may relieve pain or other symptoms when using CBD. These results may open the door for future experiments to prove a lack of toxicity and therapeutic efficacy of this formulation.

Innocan Israel, a wholly owned subsidiary of Innocan, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company (“Yissum“), the commercial arm of the Hebrew University of Jerusalem in Israel, in respect of the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoid) loaded liposomes. The development is led by Prof. Chezy Barenholz, head of the Membrane and Liposome department at the Hebrew University, who invented over 55 patent families, two of which underlie Doxil – the first FDA approved nano-drug aim for cancer treatment. This LPT unique technology platform may be effective for several applications (such as epilepsy, pain relief, and different inflammation and central nervous system disorders). A patent was filed by Innocan Israel on the LPT technology on October 7, 2019.

Prof. Chezy Berenholz, head of the Laboratory of Membrane and Liposome Research of the Hebrew University stated: ” I believe that these additional animal and efficacy studies are extremely important and may result in a major milestone. This may open a wide range of clinical applications, while maintaining the CBD level in the blood for a long period of time which may lead to better patient compliance. If successful, the technology may be beneficial for various indications”.

About Innocan

The Company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholz Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , , , , , ,
Posted in Featured, Innocan Pharma Corporation | Comments Off on Innocan $INNO.ca Moves to an Advanced Efficacy Trial on Animals of Its Liposome-CBD Injection, Following Encouraging Results on the First Stage $CGC.ca $APHA $OVAT.ca $KHRN.ca

Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab Receives Record Order in Excess of $1,000,000 for COVID-19 Tests from Film and Television Production $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:52 AM on Monday, November 16th, 2020
  • Announced that Kai Medical Laboratory has received a record COVID-19 testing order that is anticipated to be in excess of $CAD 1,000,000
  • Today’s announcement represents a repeat and significantly higher purchase order of 9,000 RT-PCR tests to be processed over a four-month period by Kai Medical Laboratory.

VANCOUVER BC / November 16, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to announce that Kai Medical Laboratory (“KAI”) has received a record COVID-19 testing order that is anticipated to be in excess of $CAD 1,000,000.

9,000 TEST ORDER FOR FILM & TELEVISION PRODUCTION REPRESENTS REPEAT AND RECORD ORDER

In early October, shortly after the acquisition of KAI, Empower announced an agreement to process approximately 1,000 COVID-19 RT-PCR tests for a major film & TV production over a 30-day period, with the possibility of more business upon successful completion of the initial tests.

Today’s announcement represents a repeat and significantly higher purchase order of 9,000 RT-PCR tests to be processed over a four-month period by Kai Medical Laboratory. The total revenue from this order is anticipated to be in excess of $CAN 1,000,000.

Empower Clinics Chairman and CEO, Steven McAuley, stated “Just three days ago we were happy to inform our shareholders that KAI had achieved a record month in October with 1,375 units, as well as, signed numerous new commercial testing contracts, the details of which were to be provided in subsequent press releases. Today’s contract is not one of those contracts. We were informed of this contract at the close of business on Friday. As I said on Friday, the magnitude of KAI’s growth and success can not be overstated. Though we are very happy with today’s record order announcement, these 9,000 tests represent only a fraction of the lab’s capacity of 4,000 COVID-19 RT-PCR tests per day. It is our intention to build on this big success and continue ramping up growth significantly through 2020 and well into 2021.”

NEWLY ACQUIRED KAI MEDICAL LABORATORY HAS PROCESSED TESTS FOR SIX FILM AND TELEVISION PRODUCTIONS

As of September 1st, KAI has already processed tests for six different film and television productions in key US markets including Los Angeles, Atlanta, New York, Dallas and continues to build both confidence and credibility within the industry.

FILM AND TV STUDIOS SEEK FAST AND RELIABLE TESTING SOLUTIONS TO RESUME SAFE OPERATIONS AND MITIGATE BILLIONS IN LOSSES

Total earnings at the North American box office in 2019 amounted to $USD 11.32 billion indicated by Statistica.com. In January 2020, the U.S. motion picture and sound recording industry employed over 456 thousand people, with several hundred thousand more in Canada, U.K. and around the world.

As a result of production closures and cinema shutdowns related to COVID-19, the majority of the industry’s revenues and jobs have been temporarily lost and are now at significant risk of long-term damage, if the industry is unable to find solutions that can provide for the safe resumption of operations.

Specifically, the global film and television industry is projected to lose a staggering $160 billion of growth over the next five years, according to research firm Ampere Analysis.

On November 2nd, AMC Theatres announced a 91% drop in revenues during the most recent earnings period, with losses hitting $906 million in just one quarter.

Empower believes it is ideally positioned through Kai Medical Laboratory to deliver one element of the overall solution with reliable, accurate and fast 24-hour COVID-19 RT-PCR testing, which is the gold standard of testing.

KAI MEDICAL LAB GROWTH STRATEGIES & NEW COMMERCIAL TESTING CONTRACTS

The Company is now implementing aggressive growth strategies, including servicing new COVID-19 testing contracts for the film & television industry, as well as, supporting the Sun Valley Health COVID-19 RT-PCR and rapid antibody testing programs in the state of Arizona.

To this end, Empower has signed numerous new commercial testing contracts, the details of which will be provided in subsequent press releases.

To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.

Texas program https://www.testtexasnow.com

Arizona program https://www.covidtest2u.com

The combination of all this commercial activity since the October 6th acquisition provides the Company with the confidence necessary to support the expectation of much further growth in the months to come.

COVID-19 RT-PCR TESTING IS THE GOLD STANDARD THAT ALLOWS EMPOWER TO ROLL OUT NATIONAL PHASE 4 TESTING PROGRAMS

KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including movie and television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: , , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab Receives Record Order in Excess of $1,000,000 for COVID-19 Tests from Film and Television Production $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

« Older Entries
Newer Entries »